Skip to main content
Clinical Trials/JPRN-UMIN000044380
JPRN-UMIN000044380
Completed
未知

Assessment of community pharmacies' support for smoking cessation treatment in collaboration with medical institutions - Assessment of community pharmacies' support for smoking cessation treatment in collaboration with medical institutions

School of Pharmacy, Nihon University0 sites70 target enrollmentJune 1, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Smoking cessation
Sponsor
School of Pharmacy, Nihon University
Enrollment
70
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 1, 2021
End Date
June 30, 2024
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
School of Pharmacy, Nihon University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Patients in the hospital 2\. Patients continuing smoking cessation treatment 3\. Men and women under the age of 20 4\. Patients who did not get their consent to participate in the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Evaluation of efficacy of the community pharmacy intervention to optimize serum potassium levels in patients with chronic kidney diseasechronic kidney disease
JPRN-UMIN000049814ational Hospital Organization Mie Chuo Medical Center40
Recruiting
Not Applicable
Increasing Community Pharmacy Involvement in the Prevention of Cardiovascular Disease Project
ACTRN12609000705280Monash450
Not yet recruiting
Not Applicable
Evaluating the feasibility and acceptability of the MedsCheck Plus service amongst community pharmacists and home-dwelling people living with dementia
ACTRN12622001172796niversity of New South Wales (UNSW)25
Active, not recruiting
Not Applicable
A community pharmacy based investigation in the self-medication areaEfficacy and safety of Sinutab® [Paracetamol (500mg) and Pseudoephedrine (30mg)] on subjects with nasal congestion accompanied by headache in the setting of a common coldThe medical rationale = to investigate this combination drug in the symptomatic relief of common cold with nasal symptoms. The reduction of symptom severity may allow subjects receiving active medication to return to work or school earlier than those receiving placebo. To study the drug in it’s ‘natural environment’, community pharmacists will function as local investigators. They will include subjects with early (= 48 hours) cold symptoms of blocked nose with headache.
EUCTR2006-000058-35-BEPfizer Consumer Healthcare Comm. VA/SCA
Active, not recruiting
Not Applicable
A community pharmacy based investigation in the self-medication areaEfficacy and safety of Sinutab® (Paracetamol (500mg)/Pseudoephedrine (30mg)) on subjects with nasal congestion accompanied by headache and/or fever in the setting of a common coldMedical rationale= Investigation of combination drug Sinutab in symptomatic relief of common cold with nasal symptoms. Community pharmacists are considered as local investigators including subjects with early (= 48 hours) cold symptoms of blocked nose with headache and/or fever.
EUCTR2004-001637-41-BEPfizer Consumer Healthcare cva/sca